Covered Outpatient Drug Final Rule and Interim Final Rule (CMS-2345-F2 and 2345-IFC2)

Today, the Centers for Medicare & Medicaid Services (CMS) issued a final rule and an interim final rule with comment period, both regarding policy for line extension drugs. The final rule responds to comments the agency has received on the definition of line extension drugs.

The interim final rule with comment revises the portion of the Medicaid Drug Rebate program’s regulatory text that describes the line extension rebate calculation to implement the statutory change to this calculation that was passed in the BBA of 2018.

• FINAL RULE
• Covered Outpatient Drug Policy